National Underutilization of Neoadjuvant Chemotherapy for Gastric Cancer

ConclusionsTen years after the publication of the MAGIC trial, fewer than 1/3 of patients with stage II/III gastric cancer are receiving neoadjuvant chemotherapy, which has been shown to improve disease-specific survival. Further studies are needed to understand these disparities and ensure both patients and providers are having evidence-based discussions about multimodal therapy for gastric cancer.

http://link.springer.com/10.1007/s11605-019-04439-y

Source: Journal of Gastrointestinal Surgery - December 1, 2019 Category: Surgery Source Type: research